News

Chordate Medical publishes company description in connection with the change of listing to Nasdaq First North Growth Market

10 February, 2022

Chordate Medical AB (publ) ("Chordate" or "the Company") has today published a company description due to the Company's planned list change ("List change") to Nasdaq First North Growth Market. The company description is available in Swedish on Chordate's website, https://www.chordate.com/investor-relations/bolagsbeskrivning/.

On January 31, 2022, Chordate announced that the Company has received preliminary approval from Nasdaq Stockholm AB ("Nasdaq") regarding the List change. The first day for trading on the Nasdaq First North Growth Market is tentatively February 15th, 2022, subject to Chordate receiving final approval from Nasdaq, with the last day for trading on the Nordic SME being February 14th, 2022. Provided that Chordate receives final approval from Nasdaq, the company's shares will continue to be traded under the short name CMH with the current ISIN code SE0009495559. Shareholders in Chordate will not have to take any action in the event of a change of trading venue.

The Company description is not deemed to contain any previously unpublished information that could have a material effect on the price of the Company's share.

Advisor
Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the planned list change and Certified Adviser. Wistrand Advokatbyrå AB is Chordate's legal advisor.

Information:
This disclosure was submitted for publication, through the contact person below, on February 10th, 2022, at 16:00 am CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

Vastra Hamnen Corporate Finance AB, +46 40 200 250, ca@vhcorp.se, is Chordate's Certified Adviser.

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM - SME (ticker: CMH). Read more at 
https://www.chordate.com/en/

Fler Nyheter

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate's share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

 

Contact us

The information is handled according to our  privacy policy.